CTY
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- City Therapeutics announced that the first participant was dosed in its Phase 1 clinical trial of CITY-RBP4 for the treatment of Stargardt disease.Nov 10, 2026
- City Therapeutics announced that Phase 1 data for CITY-FXI, an RNAi therapeutic candidate for thromboembolic diseases, was selected for oral presentation at the 68th ASH Annual Meeting.Nov 5, 2026